Background. Acute otitis media (AOM) induces middle-ear effusion (MEE), which affects hearing. The effect of antimicrobial treatment on the resolution of MEE is controversial, and the factors that affect resolution are unknown.
Most previous randomized double-blind placebo-controlled studies on the treatment of AOM have found that antimicrobial treatment does not affect the resolution of MEE [5] [6] [7] [8] [9] . Those studies, however, had relatively long follow-up intervals, which might have hindered the observance of a disappearance and reappearance of MEE [10] . Therefore, they did not report the time to resolution of MEE but, instead, its prevalence. Recently, Tapiainen et al [11] found that antimicrobial treatment significantly accelerates the resolution of MEE. They performed a close 2-month follow-up that included daily parental tympanometry; however, a majority of their study patients were older than 24 months and, thus, beyond the age to be at high risk for the persistence of MEE.
We previously reported the results of the primary outcome of our randomized double-blind placebo-controlled study on the treatment of AOM in young children. Amoxicillin-clavulanate accelerated improvement of the children's overall condition and the resolution of individual symptoms such as fever [12] . We closely followed the resolution of MEE for 3 months. Here, we report the results of our prespecified secondary objective, which was to determine the effect of antimicrobial treatment on the time to resolution of MEE and which factors affect the resolution of MEE, including factors during follow-up as a novel aspect.
METHODS

Patients and Diagnostic Criteria
Children aged 6 to 35 months were eligible for our diagnostic screening when their parents suspected AOM on the basis of the child's acute symptoms. A list of the exclusion criteria, along with their reasons, is provided in Supplementary Methods. The inclusion criterion was AOM as diagnosed by a study physician. The diagnosis of AOM required the following 3 criteria. First, the child's MEE had to be detected by means of pneumatic otoscopic examination that revealed at least 2 of the following tympanic-membrane findings: bulging position, decreased or absent mobility, abnormal color or opacity not caused by scarring, and/or air-fluid interfaces. Second, at least 1 of the following acute inflammatory signs in the tympanic membrane had to be present: distinct erythematous patches or streaks and/or increased vascularity over a full, bulging, or yellow tympanic membrane. Third, the child had to have acute symptoms of AOM. A parent of each child provided written informed consent. The protocol was approved by the ethics committee of the Hospital District of Southwest Finland.
Study Design and Follow-Up
This randomized double-blind placebo-controlled study was initiated by the investigators and was conducted independently of any commercial entities. Our primary objective was to study the efficacy of antimicrobial therapy on treatment failure, and the secondary objective, reported here, was to study the efficacy of antimicrobial treatment for the resolution of MEE. Our hypothesis was that amoxicillin-clavulanate would accelerate the resolution of MEE. Another objective was to study which factors characterized at study entry and which factors documented during follow-up affected the resolution of MEE.
Eligible patients were assigned randomly to receive amoxicillin-clavulanate (40/5.7 mg/kg, divided into 2 daily doses) or placebo for 7 days. The placebo was similar to the active treatment in appearance and taste. The description of the study drugs, the randomization procedure, the procedure for concealment of study assignments, and details of the rescue treatment and other open antimicrobial treatments are provided in Supplementary Methods.
After the enrollment visit (study day 1), we followed the patients to determine when/if their MEE resolved and the development of recurrences of AOM by closely scheduled visits on study days 3, 8, 15, 30 (45, if MEE had not resolved earlier), and 60. Thereafter, the patients who had persistent MEE were followed up every other week until study day 90 (±10 days) or until referral to tympanostomy tube placement. Apart from the scheduled visits, we arranged additional sick visits for any patient on any day of the week if the parents were concerned about their child's condition or if they suspected AOM. At each visit, the study physician interviewed the parents about the symptoms of their child, performed a clinical examination (including thorough pneumatic otoscopic and tympanometry examinations), and acquired a nasopharyngeal sample for the detection of respiratory viruses and bacteria (see details in Supplementary Methods). If AOM was diagnosed, the first episode was treated primarily with amoxicillin-clavulanate, and subsequent episodes were treated with amoxicillin.
This study was registered at ClinicalTrials.gov (identifier NCT00299455).
Outcome
The outcome was the time to resolution of MEE. The time was from the day of random assignment to the day on which a study physician confirmed the resolution of MEE, which was based on a pneumatic otoscopic assessment; both tympanic membranes had to have good mobility, complete or partial transparency, and no visibly remnant effusion.
Statistics
The sample size had been calculated for the primary outcome (see Supplementary Methods), the results of which were published previously [12] . No separate sample-size calculations had been made for the secondary outcome reported here.
All analyses were made in the intention-to-treat population. The medians and means of the time-to-outcome data were analyzed with the Kaplan-Meier method and compared with results of the log-rank test. Cox regression was used to study the effect of treatment allocation and of predefined factors on the resolution of MEE. In this work, a hazard ratio of <1.0 indicates that the factor prolonged the time to MEE resolution, and a hazard ratio of >1.0 indicates that the factor accelerated the time to MEE resolution . Proportions of patients were compared with the χ 2 or Fisher exact test, as appropriate. All P values are 2-sided. The analyses were conducted with SPSS 22 (IBM SPSS Statistics, IBM Corporation, Armonk, NY) by Dr Ruohola. Details of the statistics and definitions for the factors included in the analyses are provided in Supplementary Methods.
RESULTS
Study Population
The intention-to-treat population included 319 patients, 161 in the amoxicillin-clavulanate group and 158 in the placebo group, 53 (34%) of whom received delayed amoxicillin-clavulanate treatment as rescue therapy (see Supplementary Figure 1 ). The characteristics of the treatment groups were balanced ( Table 1) .
Effects of Amoxicillin-Clavulanate on MEE Resolution
The median time to resolution of MEE was 20 days (95% confidence interval [CI], 16-24 days) in patients who were allocated to the amoxicillin-clavulanate group and 29 days (95% CI, 26-32 days) in patients who were allocated to the placebo group (P = .10) ( Figure 1A ). The complete resolution of MEE was confirmed during the 3-month follow-up in 138 (86%) of the 161 patients in the amoxicillin-clavulanate group and in 132 (84%) of the 158 patients in the placebo group (P = .59). Additional details of the effects of amoxicillin-clavulanate are provided in Table 2 .
Factors That Affect MEE Resolution
Details of the univariable analyses are presented in Supplementary Table 1 . The factors that tended (P < .15) to shorten the time to resolution of MEE during the entire 3-month follow-up period were amoxicillin-clavulanate, unilaterality of AOM at entry, and a peaked tympanogram at entry. In contrast, age less than 24 months tended (P < .15) to prolong the time to resolution of MEE, as did the following factors, characterized during follow-up: a recurrence of AOM any time after the 7-day study-drug period and before the resolution of MEE, open antimicrobial treatment, laboratory-confirmed respiratory viral infection, and nasopharyngeal bacterial colonization.
The factors that remained significant in the multivariable analyses are shown in Figure 2 . During the entire 3-month follow-up period, a recurrence of AOM, respiratory viral infection, and nasopharyngeal bacterial colonization prolonged the resolution of MEE. Of the factors characterized at entry, a peaked tympanogram indicated a favorable prognosis. Age less than 24 months indicated an unfavorable prognosis; the hazard ratio for the time to MEE resolution was 0.74 (95% CI, 0.55-1.01; P = .06). However, age was excluded from the final step of the model, because its P value exceeded the predefined level of significance.
During the first month of the 3-month follow-up period, the independent factors that prolonged the resolution of MEE were a recurrence of AOM, respiratory viral infection, and nasopharyngeal bacterial colonization. Favorable prognostic factors were unilaterality of AOM and a peaked tympanogram at entry. During the second and third months of the 3-month follow-up period, a recurrence of AOM independently prolonged the resolution of MEE, whereas a peaked tympanogram was a favorable prognostic factor. Unfavorable prognostic factors were age less than 24 months and a sibling(s) in the household, both only during the third month of the 3-month follow-up period.
Effect of a Recurrence of AOM During Follow-Up
A recurrence of AOM at any time after the 7-day study-drug period significantly prolonged the resolution of MEE ( Figure  1B ). As Figure 3 shows, the median time to MEE resolution was longest in 100 patients who had at least 1 recurrence (67 days [95% CI, 49-85 days]) and, in contrast, shortest in 219 patients who did not have a recurrence of AOM (15 days [95% CI, 14-16]) (P < .001). The resolution of MEE was documented in 65 (65%) of 100 patients with a recurrence and 205 (94%) of 219 patients without a recurrence (P < .001). According to posthoc subgroup analyses, the disadvantageous effect of a recurrence of AOM on MEE resolution was not modified by amoxicillin-clavulanate treatment or any of the factors characterized at entry or documented during follow-up (see Supplementary  Figure 2 ).
Association of the Symptomatic Relief With the Resolution of MEE
The hazard ratios for being asymptomatic by day 8 and day 16 for the time to the MEE resolution were 0.95 (95% CI, 0.74-1.23; P = .70) and 1.23 (95% CI, 0.96-1.61; P = .09), respectively. 
DISCUSSION
In this study, treatment of AOM with amoxicillin-clavulanate in young children did not shorten the time to MEE resolution significantly; instead, new episodes of AOM during follow-up remarkably prolonged MEE. Our finding that treatment with amoxicillin-clavulanate shortly accelerated the resolution of MEE but did not significantly shorten its overall duration is, at first sight, inconsistent with results from a recent study by Tapiainen et al [11] , because they concluded that amoxicillin-clavulanate effectively reduces the duration of MEE. However, closer observation revealed that this inconsistency can be explained by the age differences in the study populations. Our study population was at high risk of MEE persistence and AOM recurrence because the mean age was 1.3 years, whereas the population of the Tapiainen et al [11] study was at low risk because the mean age was 4.4 years. In these 2 studies among children younger than 24 months, the mean MEE durations in the amoxicillin-clavulanate and placebo groups were very similar; both studies had an approximately 1-week difference in MEE durations between the treatment groups. Hoberman et al [13] had short follow-up intervals and a study design and population also otherwise comparable to ours. They observed a significant difference between treatment groups in the persistence of MEE at their final follow-up visit 3 weeks after entry. Similarly, Kaleida et al [14] detected a significant difference 2 weeks after study entry. We also observed a statistically significant treatment effect at 2 and 3 weeks, which indicates that antimicrobial treatment accelerated the resolution of MEE. However, our results suggest that this accelerating effect was short lasting, because at 4 weeks and thereafter, no significant treatment effect was observed. The overall difference in the median duration of MEE between our study groups was 9 days, which was statistically insignificant. Other previous placebo-controlled trials did not find any differences between their antimicrobial-treatment and placebo groups [5] [6] [7] [8] [9] . However, these studies reported the prevalences of MEE instead of the persistence of MEE. Prevalence figures incorporate persistent MEE and newly developed episodes, and, as results of our analyses show, prevalence figures poorly reflect the true persistence of MEE [10] . Altogether, it seems that in older children, the favorable accelerating effect of antimicrobial treatment on MEE resolution might be sustained. In contrast, at an otitis-prone age, the effect of antimicrobial treatment on the resolution of MEE seems to be modest and short lasting and, thus, clinically insignificant. A recurrence of AOM during follow-up significantly altered the course of MEE resolution. When a recurrence of AOM was diagnosed before the resolution of effusion, only 65% of the children were free of effusion during the 3-month follow-up period, and the resolution time was almost 2 months longer than that in children without a recurrence before MEE was resolved. This finding is novel but not unexpected, because explanatory mechanisms are available. A recurrence of AOM is accompanied by respiratory viral infection, which deteriorates the function of the Eustachian tube [15] . A recurrence also reinduces inflammation and, thus, effusion in the middle ear. The formation of bacterial biofilms, common in recurrent AOM [16] , might be an explanation, although recurrences or a recent episode of AOM before study entry did not affect the resolution of MEE. Current guidelines advise differentiating between recurrent episodes of AOM and persistence of MEE (or, in other words, chronic otitis media with effusion) because the persistence of MEE can cause hearing impairment and, thus, is the primary indication for tympanostomy tube placement [3] . Our results indicate that in young children who do not have craniofacial anomalies or known immunodeficiencies, recurrences of AOM and the persistence of MEE cannot be differentiated from each other because recurrences of AOM seem to be a major reason for the persistence of MEE after the initial episode of AOM.
The prerequisites for AOM development are respiratory viral infection and nasopharyngeal bacterial colonization, most commonly by Streptococcus pneumoniae, Haemophilus influenzae, and/or Moraxella catarrhalis [17, 18] . It was an unexpected finding that these microbes independently prolonged the resolution of MEE. The effect of respiratory viral infection is probably mediated by inflammation of the respiratory epithelium, which deteriorates the function of the Eustachian tubes [15] . The effect of bacterial nasopharyngeal colonization might be caused by interaction between bacteria and viruses. We recently found that M catarrhalis is independently associated with respiratory symptoms, especially rhinitis, in young children with respiratory viral infection [19] . In our current study, the risk factors for otitis media, such as day care attendance and parental smoking, did not have remarkable effects on MEE resolution. However, in the prevention of MEE persistence, the risk factors should also be recognized. If the risk factors are reduced, the acquisition of respiratory viruses and colonizing bacteria might be reduced, Figure 2 . Forest plot of the factors that had an independent effect on the resolution of middle-ear effusion (MEE). Hazard ratios and 95% confidence intervals (CIs) for the resolution of MEE are based on a multivariable Cox regression model for the entire 3-month follow-up period and on separate models for each of the 3 follow-up months. Each of the 4 models included those patients in whom MEE had not yet resolved. In this work, a hazard ratio of <1.0 indicates that the factor prolonged the time to MEE resolution, and a hazard ratio of >1.0 indicates that the factor accelerated the time to MEE resolution.
a Total number was 319, but the model excluded 6 patients because of missing data on respiratory viral infection and nasopharyngeal bacterial colonization.
b Total number was 319, but the model excluded 10 patients, 4 because of missing data on unilateral acute otitis media and 6 because of missing data on respiratory viral infection and nasopharyngeal bacterial colonization.
c The model did not include 2 of the factors (ie, respiratory viral infection and nasopharyngeal bacterial colonization) because sampling was infrequent during the third month of follow-up. and therefore, the risk of AOM recurrences might be reduced also, which all might prevent the persistence of MEE. According to our results and those of Renko et al [20] , a favorable prognostic factor for the resolution of MEE seems to be unilaterality of AOM. However, in our study, a peaked tympanogram was the most favorable prognostic factor. This finding is logical, because a peaked tympanogram is an indicator of small volume of MEE [21, 22] ; in these instances, the bulging position of the tympanic membrane is probably a result of positive pressure in the middle ear. The drawback to using a peaked tympanogram as a prognostic factor is that it is a rare finding when stringent criteria are used to diagnose AOM.
The major strengths of our study are the nonselective study population at an otitis-prone age, the stringent diagnostic criteria, and the tight follow-up schedule. To our knowledge, our study is the first randomized double-blind placebo-controlled trial in which all patients were closely followed until MEE resolution or referral for tympanostomy tube placement; only 5% of the patients were lost to follow-up. The major methodologic limitation was the subjectivity of pneumatic otoscopy even when added with video recording. However, visibly low levels of MEE are not necessarily obtained by tympanocentesis, and tympanometry often produces a peaked curve that suggests the resolution of MEE. It is impossible currently to determine which volume of MEE is clinically relevant; therefore, we aimed to observe even small volumes of MEE and, thus, to be assured of total MEE resolution, which can be criticized. It could be questioned if a higher dose of amoxicillin-clavulanate might have been effective, although the dose (40 mg/kg per day) we chose had excellent antimicrobial coverage in our study population. A study by Hoberman et al [13] was much like ours, but they chose a dose of 90 mg/kg per day. At their 3-week final control visit, the proportions of patients who had persistent MEE were actually somewhat higher, and the difference between the study groups was smaller than that in our study. Thus, it does not seem that the dose is a major reason why amoxicillin-clavulanate had no overall effect. Our study can also be criticized for the lack of sample-size calculation for the reported secondary outcome. However, although with a larger sample size the difference between treatment-allocation groups would have been statistically significant, we would regard the observed difference to be clinically insignificant.
In conclusion, our study reveals that in young children with AOM, immediate antimicrobial treatment (such as with amoxicillin-clavulanate) that has appropriate coverage does not significantly shorten the time to MEE resolution. The major reason for inadequate resolution and, thus, for the persistence of MEE is recurrence of AOM before MEE resolution.
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